16 2023 Sarepta Therapeutics Inc NASDAQSRPT the leader in precision genetic medicine for rare diseases today announced that at its late cycle meeting for the SRP9001 delandistrogene moxeparvovec biologics license application BLA the US Food and Drug Administrations Office of Therapeutics OTP has determined that an advisory committee meeting will be held for SRP9001 in advance of the May 29 2023 regulatory action date